000099767 001__ 99767
000099767 005__ 20240319080947.0
000099767 0247_ $$2doi$$a10.1080/14737167.2021.1880324
000099767 0248_ $$2sideral$$a122932
000099767 037__ $$aART-2022-122932
000099767 041__ $$aeng
000099767 100__ $$aTaxonera, Carlos
000099767 245__ $$aCost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
000099767 260__ $$c2022
000099767 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099767 5203_ $$aBackground: To evaluate the cost-effectiveness of tofacitinib in comparison to vedolizumab for the treatment of moderate-to-severe ulcerative colitis (UC) after failure or intolerance to conventional therapy (bio-naive) or first-line biologic treatment (bio-experienced), from the Spanish National Health System (NHS) perspective.
Methods: A lifetime Markov model with eight-week cycles was developed including five health states: remission, response, active UC, remission after surgery, and death. Response and remission probabilities (for induction and maintenance periods) were obtained from a multinomial network meta-analysis. Drug acquisition – biosimilar prices included – (ex-factory price with mandatory deductions), adminis- tration, surgery, patient management, and adverse event management costs (€, year 2019) were considered. A 3% discount rate (cost/outcomes) was applied. Probabilistic and deterministic sensitivity analyses (PSA) were conducted.
Results: Tofacitinib was dominant versus vedolizumab (both in bio-naive and bio-experienced patients) entailing total cost savings of €23,816 (bio-naïve) and €11,438 (bio-experienced). Differences in quality- adjusted life-year (QALY) were smaller than 0.1 for both populations. PSA results showed that tofacitinib has a high probability of being cost-effective (bio-naïve: 82.5%; bio-experienced: 90.6%) versus vedolizumab.
Conclusions: From the Spanish NHS perspective, tofacitinib could be a dominant treatment (less costly and more effective) in comparison to vedolizumab, with relevant cost savings and similar QALY gains.
000099767 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000099767 590__ $$a2.3$$b2022
000099767 592__ $$a0.596$$b2022
000099767 591__ $$aHEALTH CARE SCIENCES & SERVICES$$b72 / 106 = 0.679$$c2022$$dQ3$$eT3
000099767 593__ $$aHealth Policy$$c2022$$dQ2
000099767 591__ $$aHEALTH POLICY & SERVICES$$b59 / 87 = 0.678$$c2022$$dQ3$$eT3
000099767 593__ $$aPharmacology (medical)$$c2022$$dQ2
000099767 591__ $$aPHARMACOLOGY & PHARMACY$$b200 / 278 = 0.719$$c2022$$dQ3$$eT3
000099767 593__ $$aMedicine (miscellaneous)$$c2022$$dQ2
000099767 594__ $$a3.4$$b2022
000099767 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099767 700__ $$ade Andrés-Nogales, Fernando
000099767 700__ $$0(orcid)0000-0003-3970-5457$$aGarcía-López, Santiago$$uUniversidad de Zaragoza
000099767 700__ $$aSánchez-Guerrero, Amelia
000099767 700__ $$aMenchén, Belén
000099767 700__ $$aPeral, Carmen
000099767 700__ $$aCábez, Ana
000099767 700__ $$aGómez, Susana
000099767 700__ $$aLópez-Ibáñez de Aldecoa, Alejandra
000099767 700__ $$aCasado, Miguel Ángel
000099767 700__ $$aMenchén, Luis
000099767 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000099767 773__ $$g22, 1 (2022), 73-83$$pExpert Review of Pharmacoeconomics and Outcomes Research$$tExpert Review of Pharmacoeconomics and Outcomes Research$$x1473-7167
000099767 8564_ $$s2270609$$uhttps://zaguan.unizar.es/record/99767/files/texto_completo.pdf$$yVersión publicada
000099767 8564_ $$s3269706$$uhttps://zaguan.unizar.es/record/99767/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099767 909CO $$ooai:zaguan.unizar.es:99767$$particulos$$pdriver
000099767 951__ $$a2024-03-18-12:41:04
000099767 980__ $$aARTICLE